Description: Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; Dysport for motor muscular disorders and medical aesthetics; NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, chronic renal failure, and GH deficiency in adults; and Increlex for growth failure in children and adolescents. The company also offers Smecta for chronic and acute diarrhea, and pain associated with functional bowel diseases; Forlax for constipation; Fortrans/Eziclen for bowel cleansing prior to endoscopy, X-ray examination, and colonic surgery; and Tanakan for cognitive disorders in adults, vertigo of vestibular origin and vestibular rehabilitation, and tinnitus. In addition, it provides Xermelo for the carcinoid syndrome; Cometriq for medullary thyroid cancer; Smebiocta/SmectaFlora Protect, a food supplement; SmectaGas, a medical device used in the symptomatic treatment of gas-related gastrointestinal disorders and relief of gas-related symptoms; and Etiasa for inflammatory bowel diseases. Further, the company offers other consumer healthcare products in the gastro-intestinal area, including Buscopan, Clin4000, Prontalgine, Suppositoria Glycerini, Mucothiol, Floractin, and Mucodyne. Ipsen S.A. has agreements with Debiopharm; Exelixis; Galderma; Blueprint Medicines; TerSera Therapeutics; Rhythm Pharmaceuticals; Teijin; Braintree Laboratories; Ethypharm; Schwabe; BAKX Therapeutics Inc.; and Exicure. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France.
Home Page: www.ipsen.com
65 Quai Georges Gorse
Boulogne-Billancourt,
92100
France
Phone:
33 1 58 33 50 00
Officers
| Name | Title |
|---|---|
| Mr. David Loew | MD, CEO & Director |
| Mr. Aymeric Le Chatelier | Exec. VP & Group CFO |
| Dr. Aidan Murphy Ph.D. | Exec. VP of Technical Operations |
| Mr. Craig Marks | Vice-Pres of Investor Relations |
| Mr. Francois Garnier | Exec. VP of Legal Affairs, Gen. Counsel & Chief Bus. Ethics Officer |
| Ms. Gwenan White | Exec. VP of Communications & Public Affairs |
| Mr. Regis Mulot | Exec. VP & Chief HR Officer |
| Mr. Stephan Gagne | Head of New Tokyo Office |
| Ms. Dominique Bery | Head of Nordics & Baltics |
| Dr. Yan Moore M.D. | Sr. VP & Head of Oncology Therapeutic Area |
Exchange: PA
Country: FR
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 12.1803 |
|---|---|
| Trailing PE: | 11.4915 |
| Price-to-Book MRQ: | 2.8846 |
| Price-to-Sales TTM: | 2.6241 |
| IPO Date: | 2005-12-07 |
| Fiscal Year End: | December |
| Full Time Employees: | 4500 |